Global Blood Therapeutics
Latest round
- Series B
Last raised
- Dec 2014
Total raised
- $89M
Investors
- 6
About Global Blood Therapeutics
Global Blood Therapeutics, Inc.Founded in 2012, Global Blood Therapeutics, Inc. is headquartered in San Francisco, US.4 bn.Global Blood Therapeutics specializes in the development and commercialization of therapies for sickle cell disease and other serious blood disorders. Its flagship product, voxelotor, received FDA approval in November 2019 and is designed to increase hemoglobin levels in patients with sickle cell disease, thereby reducing painful vaso-occlusive crises.51 mn, primarily generated through the sale of voxelotor via pharmacies and healthcare providers. to accelerate its lead drug candidate, GBT440, for the treatment of sickle cell disease. The company aims to explore new markets and geographic regions, focusing on expanding its presence in Europe and other international markets by late 2023.
Who invested in Global Blood Therapeutics
6 investors across 2 rounds
See all investors in Global Blood Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Global Blood Therapeutics
Who invested in Global Blood Therapeutics?
Global Blood Therapeutics has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Global Blood Therapeutics raised?
Global Blood Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Global Blood Therapeutics last raise money?
Global Blood Therapeutics's most recent round on record is a Series B, in Dec 2014.
What does Global Blood Therapeutics do?
Global Blood Therapeutics, Inc.
Where is Global Blood Therapeutics headquartered?
Global Blood Therapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Global Blood Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Global Blood Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Global Blood Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.